Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis

doi:10.4254/wjh.v11.i4.391

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9071)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

395

WORD

258

HTML

5030

Figures (1-2)

336

Tables (1-2)

246

Sum=6265

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

955

Download

1851

Sum=2806

Apr 27, 2019 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Apr 27, 2019; 11(4): 391-401
Published online Apr 27, 2019. doi: 10.4254/wjh.v11.i4.391

Table 1 Characteristics of 83 patients with hidradenitis suppurative, Nonalcoholic fatty liver and Nonalcoholic steatohepatitis and intercalsses charactersitics

	HS only	NAFLD	P value	NASH	P value	NAFL	P value
n	51	32		12		20
Age, mean(SD)	43.04 (8.9)	41.32 (9.0)	0.564	41.58 (7.4)	0.602	40.55 (10.3)	0.315
Age cat (%)			0.646		0.463		0.629
< 30	3 (5.9)	4 (12.5)		1 (8.3)		3 (15.0)
30-39	16 (31.4)	8 (25.0)		2 (16.7)		6 (30)
40-49	18 (35.3)	14 (43.8)		7 (58.3)		7 (35.0)
> 50	14 (27.5)	6 (18.8)		2 (16.7)		4 (20.0)
Male, n (%)	17 (33.3)	14 (43.8)	0.623	5 (41.7)	0.835	9 (45.0)	0.52
Diabetes, n (%)	12 (23.5)	9 (28.1)	0.853	3 (25.0)	0.764	6 (30.0)	0.794
BMI, mean(SD)	28.31 (2.5)	27.56 (1.9)	0.381	27.58 (2.7)	0.376	27.55 (1.7)	0.218
bmi_cat (%)			0.559		0.515		0.384
Normal Weight	4 (7.8)	4 (12.5)		2 (16.7)		2 (10.0)
Overweight	38 (74.5)	26 (81.3)		9 (75.0)		17 (85.0)
Obese	9 (17.6)	2 (6.3)		1 (8.3)		1 (5.0)
IHS4, mean(SD)	9.57 (3.6)	11.32 (2.8)	0.025	12.67 (3.6)	0.009	9.40 (3.9).	0.861
IHS4 cat (%)			0.028		0.007		0.97
Mild	5 (9.8)	3 (9.4)		1 (8.3)		2 (10.0)
Moderate	24 (47.1)	10 (31.3)		0 (0)		10 (50.0)
Severe	22 (43.1)	19 (59.4)		11 (91.7)		8 (40)
Hurley (%)			0.494		0.197		0.785
1	5 (9.8)	3 (9.4)		1 (8.3)		2 (10.0)
2	24 (47.1)	6 (18.8)		1 (8.3)		5 (25.0)
3	22 (43.1)	23 (71.9)		10 (83.3)		13 (65.0)
Elevated_liver_enzymes, n (%)	19 (37.3)	9 (28.1)	0.617	4 (33.3)	0.998	5 (25.0)	0.482
ADDI_score, mean(SD)	2.55 (1.4)	3.72 (1.8)	< 0.001	5.33 (2.2)	< 0.001	2.75 (1.6)	0.603
Inflammatory comorbidities, n (%)	2 (3.9)	12 (37.5)	< 0.001	7 (58.3)	< 0.001	5 (25.0)	0.025
In detail (%)			0.001		< 0.001		0.047
Acne conglobata	1 (2.0)	0 (0)		0 (0)		0 (0)
Crohn disease	0 (0)	2 (6.3)		1 (8.3)		1 (5.0)
Lichen sclerosus	1 (2.0)	0 (0)		0 (0)		0 (0)
PASH	0 (0)	5 (15.6)		4 (33.3)		1 (5.0)
Psoriasis	0 (0)	2 (6.3)		1 (8.3)		1 (5.0)
Spondyloarthritis	0 (0)	2 (6.3)		1 (8.3)		1 (5.0)
Uveitis	0 (0)	1 (3.1)		0 (0)		1 (5.0)
Positive ultrasound, n (%)	11 (21.6)	32 (100.0)	< 0.001	12 (100.0)	< 0.001	20 (100.0)	< 0.001
NASH	0 (0)	12 (37.5)	< 0.001	12 (100.0)		0 (0)
NAFL	0 (0)	20 (62.5)	< 0.001	0 (0)		20 (100.0)

ADDI: Autoinflammatory disease damage index; BMI: Body mass index; HS: Hidradenitis suppurativa; IHS4: International Hidradenitis Suppurativa Severity Scoring System, NASH: NonAlcoholic SteatoHepatitis, NAFL: NonAlcoholic Fatty Liver, PASH: Pyoderma gangrenosum, Acne, and hidradenitis suppurativa; SD: Standard deviation. Normal weight: 18.5–24.9 kg/m², Overweight: 25–29.9 kg/m² Obese: >29. 9 kg/m².

Table 2 Differences among hidradenitis suppurativa patients with and without diabetes

	Non diabetes	Diabetes	P value
n	62	21
Age, mean(SD)	42.44 (9.4)	41.62 (8.2)	0.722
Age cat (%)			0.203
< 30	4 ( 6.5)	3 (14.3)
> 50	17 (27.4)	3 (14.3)
30-39	20 (32.3)	4 (19.0)
40-49	21 (33.9)	11 (52.4)
Male, n (%)	21 (33.9)	10 ( 47.6)	0.387
Diabetes, n (%)	0 ( 0.0)	21 (100.0)	<0.001
BMI, mean(SD)	28.10 (2.6)	27.81 (1.4)	0.636
bmi_cat (%)			0.161
Normal Weight	8 (12.9)	0 ( 0.0)
Obese	9 (14.5)	2 ( 9.5)
Overweight	45 (72.6)	19 ( 90.5)
IHS4, mean(SD)	10.37 (3.6)	8.81 (4.1)	0.101
IHS4 cat, n (%)			0.051
Mild	4 ( 6.5)	4 ( 19.0)
Moderate	23 (37.1)	11 ( 52.4)
Severe	35 (56.5)	6 ( 28.6)
Hurley, n (%)			0.022
1	4 ( 6.5)	4 ( 19.0)
2	14 (22.6)	9 ( 42.9)
3	44 (71.0)	8 ( 38.1)
Elevated_liver_enzymes, n (%)	21 (33.9)	7 ( 33.3)	1
ADDI_score, mean(SD)	3.13 (1.8)	2.62 (2.0)	0.275
Inflammatory comorbidities, n (%)	9 (14.5)	5 ( 23.8)	0.518
In.detail, n (%)			0.563
	53 (85.5)	16 ( 76.2)
Acne conglobata	1 ( 1.6)	0 ( 0.0)
Crohn	1 ( 1.6)	1 ( 4.8)
Lichen sclerosus	0 ( 0.0)	1 ( 4.8)
PASH	4 ( 6.5)	1 ( 4.8)
Psoriasis	1 ( 1.6)	1 ( 4.8)
Spondyloarthritis	1 ( 1.6)	1 ( 4.8)
Uveitis	1 ( 1.6)	0 ( 0.0)
Positive_ultrasound, n (%)	31 (50.0)	12 ( 57.1)	0.754
NASH, n (%)	9 (14.5)	3 ( 14.3)	1
NAFL, n (%)	14 (22.6)	6 ( 28.6)	0.795
Disease, n (%)			0.853
HS only	39 (62.9)	12 ( 57.1)
NAFL	14 (22.6)	6 ( 28.6)
NASH	9 (14.5)	3 ( 14.3)

ADDI: Autoinflammatory Disease Damage Index; BMI: Body mass index; HS: Hidradenitis suppurativa; IHS4: International Hidradenitis Suppurativa Severity Scoring System; NASH: Non-alcoholic steatohepatitis; NAFL: Nonalcoholic fatty liver; PASH: Pyoderma gangrenosum, Acne, and hidradenitis suppurativa; SD: Standard deviation. Normal weight: 18.5–24.9 kg/m²; Overweight: 25-29.9 kg/m²; Obese: > 29.9 kg/m².

Citation: Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR, Pigatto PD, Maiorana C, Poli P, Berti E, Pace MC, Malagoli P, Bettoli V, Fiore M. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 2019; 11(4): 391-401
URL: https://www.wjgnet.com/1948-5182/full/v11/i4/391.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i4.391